Premium
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV ‐1‐infected patients: a cohort study
Author(s) -
Gantner P,
Reinhart S,
Partisani M,
Baldeyrou M,
Batard ML,
BernardHenry C,
Cheneau C,
Mautort E,
Priester M,
FafiKremer S,
Muret P,
Rey D
Publication year - 2015
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12183
Subject(s) - rilpivirine , medicine , emtricitabine , tenofovir , regimen , human immunodeficiency virus (hiv) , cohort , virology , pharmacology , viral load , antiretroviral therapy
Objectives Emtricitabine/tenofovir/rilpivirine as a single‐tablet regimen ( STR ) is widely used without licence in treatment‐experienced patients. The purpose of this retrospective observational study was to assess viral suppression of ART ‐experienced patients switching to STR . Methods We assessed 131 pretreated patients switching to STR with HIV RNA < 400 HIV ‐1 RNA copies/mL. The primary outcome measure was the proportion of patients at week 24 with HIV RNA < 40 copies/mL. Results By week 24, eight patients had stopped STR : four because of adverse events and four for other reasons. Three virological failures were observed; among these, at least one patient developed cross‐resistance to nucleoside reverse transcriptase inhibitors ( NRTI s) and nonnucleoside reverse transcriptase inhibitors ( NNRTIs ), in particular with the E138K pattern. In intent‐to‐treat analysis, 92% of participants (120 of 131) achieved HIV RNA < 40 copies/mL. Only grade 1 to 2 adverse events were observed, mainly consisting of increased liver enzymes (n = 33). Systemic exposure to rilpivirine was above the usually observed steady‐state levels for the 18 measurements assessed. Conclusions Efficacy and tolerability are similar to those in treatment‐naïve patients.